Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.

We have recently described an increased lymphocytic infiltration rate in breast carcinoma tissue is a significant response predictor for anthracycline/taxane-based neoadjuvant chemotherapy (NACT). The aim of this study was to prospectively validate the tumor-associated lymphocyte infiltrate as predi...

Full description

Bibliographic Details
Main Authors: Yasmin Issa-Nummer, Silvia Darb-Esfahani, Sibylle Loibl, Georg Kunz, Valentina Nekljudova, Iris Schrader, Bruno Valentin Sinn, Hans-Ullrich Ulmer, Ralf Kronenwett, Marianne Just, Thorsten Kühn, Kurt Diebold, Michael Untch, Frank Holms, Jens-Uwe Blohmer, Jörg-Olaf Habeck, Manfred Dietel, Friedrich Overkamp, Petra Krabisch, Gunter von Minckwitz, Carsten Denkert
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3846472?pdf=render

Internet

http://europepmc.org/articles/PMC3846472?pdf=render

Similar Items